Last reviewed · How we verify
NCT05297643
Effects of Extracorporeal Shock Wave Therapy Added To Complex DecongestiveTherapy In Patıent With Lymphedeme
NA trial testing Ekstracorporeal Shock Wave Therapy (ESWT) in Lymphedema, Breast Cancer in 44 participants. Status unknown.
1 December 2023
Quick facts
| Lead sponsor | Kirsehir Ahi Evran Universitesi |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 1 July 2022 |
| Primary completion | 1 December 2023 |
| Estimated completion | 15 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Ekstracorporeal Shock Wave Therapy (ESWT)
- complex decongestive therapy
Conditions studied
- Lymphedema, Breast Cancer — all drugs for Lymphedema, Breast Cancer →
Sponsor
Kirsehir Ahi Evran Universitesi — full company profile →
Who can join
Adults 18 to 65, female only, with Lymphedema, Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed . Today, it is used in musculoskeletal diseases such as plantar fasciitis, epicondylitis, achillestendinitis, and osteoarthritis. The main mechanism of action of ESWT is not clearly known, but many studies have shown that it stimulates the early release of angiogenesis-related growth factors such as endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) and increases blood circulation with induced neovascularization, resulting in cell proliferation and tissue growth. It has been shown to increase regeneration . It has been found to be effective in lymphedema with neovascularization and lymphatic channel synthesis . In the literature, there are studies investigating the additional contributions of complex decongestive therapy combined with ESWT in patients with lymphedema.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05297643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphedema, Breast Cancer
Currently open trials in the same condition.
- NCT07257679 — Gentle Touch for Post-Mastectomy Lymphedema · Phase 4 · recruiting
- NCT06302361 — Lymphovenous Anastomosis for Breast Cancer Lymphedema · NA · active not recruiting
- NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
- NCT05366699 — LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy · NA · recruiting
- NCT05601037 — LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema · NA · recruiting
Other Kirsehir Ahi Evran Universitesi trials
Trials by the same sponsor.
- NCT07506915 — The Effect of Cognitive Behavioral Therapy · NA · enrolling by invitation
- NCT07502248 — PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07438392 — Tecar Therapy in Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07450742 — Digital Storytelling and Mother's Knowledge and Attitudes Towards Newborn Screning · NA · not yet recruiting
- NCT07414017 — Comparison of Focus of Attention in Virtual Reality-Based Exercise Training in Older Adults With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05297643 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirsehir Ahi Evran Universitesi
- Last refreshed: 9 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05297643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing